Enveric Biosciences (NASDAQ:ENVB) Raised to Hold at Wall Street Zen

Enveric Biosciences (NASDAQ:ENVB) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Sunday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Enveric Biosciences in a research note on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Enveric Biosciences currently has an average rating of “Sell”.

Enveric Biosciences Stock Down 1.4%

Enveric Biosciences stock opened at $1.41 on Friday. The stock has a market cap of $6.32 million, a price-to-earnings ratio of -0.11 and a beta of 1.13. The business has a 50-day simple moving average of $1.41 and a 200 day simple moving average of $2.02. Enveric Biosciences has a 52 week low of $1.25 and a 52 week high of $17.64.

Enveric Biosciences (NASDAQ:ENVB) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.76) earnings per share (EPS) for the quarter.

About Enveric Biosciences

Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.

Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety.